FinancePrimary-confirmedconfirmedpushed to newsroomengine discovery
Eli Lilly Agrees to Buy AtaiBeckley for $2.8B Upfront and Up to $3.8B Total
Eli Lilly signed a definitive agreement to acquire psychedelic-treatment developer AtaiBeckley. Shareholders are slated to receive $6.75 per share in cash at closing, valuing the upfront consideration at about $2.8 billion, plus contingent value rights worth up to $2.50 per share if specified clinical, regulatory, and DEA-rescheduling milestones are reached. Total potential consideration is approximately $3.8 billion.
PriorityURGENT93.4
First detected1d ago
Last development1d ago
Event date2026-07-16
Sources (3)
Origin
Confirmation
- investing.comweb_articleindependentReuters — Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal4d ago · open ↗
Context
- cnbc.comweb_articleindependentCNBC — The market for psychedelic drugs to treat mental health conditions gets a big buy signal1d ago · open ↗